{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T02:45:28Z","timestamp":1789785928378,"version":"4.0.1"},"reference-count":45,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2003,1,24]],"date-time":"2003-01-24T00:00:00Z","timestamp":1043366400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Movement Disorders"],"published-print":{"date-parts":[[2003,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Piribedil is a non\u2010ergot D2\/D3 agonist with a significant antagonist action on \u03b12A and \u03b12C adrenergic receptor subtypes. This double\u2010blind placebo\u2010controlled study was undertaken to confirm the efficacy of 150 mg\/day piribedil po in improving motor symptoms of idiopathic Parkinson's disease (PD) in nonfluctuating patients insufficiently controlled by a stable daily dose of levodopa (<jats:sc>L<\/jats:sc>\u2010dopa). Efficacy was assessed using the Unified Parkinson's Disease Rating Scale (UPDRS) III score as primary criterion over 4 months. A second comparison was planned at 6 months, after possible adjustment of <jats:sc>L<\/jats:sc>\u2010dopa. At 4 months, the rate of response, defined as a 30% decrease from baseline on UPDRS III score, was significantly greater with piribedil compared with placebo (56.4% vs. 37.7%; <jats:italic>P<\/jats:italic> = 0.040). At 6 months, the better efficacy of piribedil was maintained (61.8% of responders vs. 39.6% on placebo; <jats:italic>P<\/jats:italic> = 0.020). The difference between groups on UPDRS III change from baseline reached statistical significance only at 6 months: \u221210.0 points in the piribedil group vs. \u22126.7 points in the placebo group (<jats:italic>P<\/jats:italic> = 0.037). Secondary end\u2010points were not significantly different. The most frequently reported adverse events were gastrointestinal symptoms (27 of 61 patients in the piribedil group vs. 13 of 54 patients in the placebo group). In conclusion, a 6\u2010month oral administration of 150 mg\/day piribedil in combination with <jats:sc>L<\/jats:sc>\u2010dopa is well tolerated, except for minor gastrointestinal symptoms at the beginning of the treatment and significantly improves motor symptoms compared with placebo in PD nonfluctuating patients. \u00a9 2003 Movement Disorder Society<\/jats:p>","DOI":"10.1002\/mds.10359","type":"journal-article","created":{"date-parts":[[2003,3,28]],"date-time":"2003-03-28T08:10:03Z","timestamp":1048839003000},"page":"418-425","source":"Crossref","is-referenced-by-count":52,"title":["Efficacy of piribedil as early combination to levodopa in patients with stable Parkinson's disease: A 6\u2010month, randomized, placebo\u2010controlled study"],"prefix":"10.1002","volume":"18","author":[{"given":"Marc","family":"Ziegler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alexandre","family":"Castro\u2010Caldas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Del Signore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier","family":"Rascol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2003,1,24]]},"reference":[{"key":"e_1_2_5_2_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(77)91146-1"},{"key":"e_1_2_5_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.36.11.1528"},{"key":"e_1_2_5_4_2","first-page":"65","volume-title":"Twenty years of Madopar: new avenues","author":"Marsden CD","year":"1994"},{"key":"e_1_2_5_5_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.50.6_Suppl_6.S23"},{"key":"e_1_2_5_6_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(72)90149-5"},{"key":"e_1_2_5_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(74)90111-3"},{"key":"e_1_2_5_8_2","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1016\/S0022-3565(25)12143-5","article-title":"Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)\u2010S 14297. II. Both D2 and \u201dSilent\u201d D3 autoreceptors control synthesis and release in mesolimbic, mesocortical and nigrostrial pathways","volume":"275","author":"Gobert A","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_9_2","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1016\/S0022-3565(25)12142-3","article-title":"Functional correlates of dopamine D3 receptor activation in the rat in vivo and their modulation by the selective antagonist, (+)\u2010S 14297. I. Activation of postsynaptic D3 receptors mediates hypothermia, whereas blockade of D2 receptors elicits prolactin secretion and catalepsy","volume":"275","author":"Millan MJ","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_10_2","doi-asserted-by":"publisher","DOI":"10.2165\/00023210-199810030-00004"},{"key":"e_1_2_5_11_2","doi-asserted-by":"publisher","DOI":"10.1038\/35086062"},{"key":"e_1_2_5_12_2","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1016\/S0022-3565(24)29611-7","article-title":"The antiparkinsonian agent, piribedil, displays antagonist properties at native, rat and cloned, human a2\u2010adrenoceptors: a cellular and functional characterization","volume":"297","author":"Millan MJ","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"key":"e_1_2_5_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/0014-2999(75)90325-8"},{"key":"e_1_2_5_14_2","first-page":"s89","article-title":"Reserpine\u2010induced tremor, rigidity and hypokinesia in rats: effects of piribedil in comparison with other dopaminergic agonists","volume":"237","author":"Koek W","year":"1990","journal-title":"J Neurol"},{"key":"e_1_2_5_15_2","doi-asserted-by":"publisher","DOI":"10.1126\/science.179.4075.816"},{"key":"e_1_2_5_16_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870110203"},{"issue":"3","key":"e_1_2_5_17_2","first-page":"A53","article-title":"Piribedil induces low levels of dyskinesia in MPTP\u2010treated common marmosets","volume":"54","author":"Jenner P","year":"2000","journal-title":"Neurology"},{"key":"e_1_2_5_18_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.10200"},{"key":"e_1_2_5_19_2","first-page":"S51","article-title":"Piribedil plasma levels after chronic oral administration of Trivastal Retard 50 (150 mg\/day) in parkinsonian patients","volume":"7","author":"Allain H","year":"2001","journal-title":"Parkinsonism Relat Disord"},{"key":"e_1_2_5_20_2","doi-asserted-by":"publisher","DOI":"10.1001\/archneur.1974.00490350041006"},{"key":"e_1_2_5_21_2","first-page":"373","article-title":"Indications of piribedil in L\u2010dopa\u2010treated parkinsonian patients: physiopathologic implications","volume":"9","author":"Rondot P","year":"1975","journal-title":"Adv Neurol"},{"issue":"1","key":"e_1_2_5_22_2","doi-asserted-by":"crossref","first-page":"S28","DOI":"10.1007\/BF00819564","article-title":"Activity and acceptability of piribedil in Parkinson's disease: a multicentre study","volume":"239","author":"Rondot P","year":"1992","journal-title":"J Neurol"},{"key":"e_1_2_5_23_2","doi-asserted-by":"publisher","DOI":"10.1002\/cpt19741661077"},{"key":"e_1_2_5_24_2","first-page":"56","article-title":"Effets imm\u00e9diats du pirib\u00e9dil sur le tremblement de repos","volume":"2","author":"Ziegler M","year":"1987","journal-title":"Precepta Med"},{"issue":"1","key":"e_1_2_5_25_2","first-page":"S66","article-title":"Kinetic profile and effect on tremor of piribedil in 13 parkinsonian patients during and after IV perfusion","volume":"241","author":"Ziegler M","year":"1994","journal-title":"J Neurol"},{"key":"e_1_2_5_26_2","first-page":"4","article-title":"Une \u00e9tude multicentrique d\u00e9montre l'efficacit\u00e9 et la tol\u00e9rance de Trivastal 50 mg LP prescrit en premi\u00e8re intention dans la maladie de Parkinson","volume":"1","author":"Ziegler M","year":"1991","journal-title":"JAMA"},{"key":"e_1_2_5_27_2","first-page":"1414","article-title":"Activit\u00e9 du pirib\u00e9dil dans la maladie de Parkinson. Etude multicentrique","volume":"28","author":"Ziegler M","year":"1999","journal-title":"Press Med"},{"key":"e_1_2_5_28_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0404.1975.tb05772.x"},{"key":"e_1_2_5_29_2","first-page":"453","article-title":"Etude clinique et \u00e9lectro\u2010physiologique prolong\u00e9e chez 54 parkinsoniens, d'un nouvel agoniste dopaminergique","volume":"53","author":"Truelle JL","year":"1977","journal-title":"Semain Hop Paris Ther"},{"key":"e_1_2_5_30_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.17.5.427"},{"key":"e_1_2_5_31_2","series-title":"Recent developments in Parkinson's disease","first-page":"153","author":"Fahn S","year":"1987"},{"key":"e_1_2_5_32_2","first-page":"S2b70","article-title":"Rating scales for Parkinson's disease: when and how to use them","volume":"156","author":"Bonnet A\u2010M","year":"2000","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_5_33_2","first-page":"152","volume-title":"Third SYMPOSIUM on Parkinson's disease","author":"Schwab RS","year":"1969"},{"key":"e_1_2_5_34_2","first-page":"S59","article-title":"Piribedil improves vigilance and disability in MPTP treated common marmosets more than L\u2010dopa","volume":"7","author":"Jenner P","year":"2001","journal-title":"Parkinsonism Relat Disord"},{"issue":"3","key":"e_1_2_5_35_2","first-page":"115","article-title":"The safety pf pergolide monotherapy in early\u2010stage Parkinson's disease. One\u2010year interim analysis of a 3\u2010year double blind, randomized study of pergolide versus levodopa","volume":"15","author":"Hundemer HP","year":"2000","journal-title":"Mov Disord"},{"key":"e_1_2_5_36_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200005183422004"},{"key":"e_1_2_5_37_2","doi-asserted-by":"publisher","DOI":"10.1002\/mds.870130112"},{"key":"e_1_2_5_38_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.52.9.1908"},{"issue":"3","key":"e_1_2_5_39_2","first-page":"110","article-title":"A comparative study of daytime sleepiness within Parkinson's disease patients treated with cabergoline, pramipexole and levodopa","volume":"15","author":"Pal S","year":"2000","journal-title":"Mov Disord"},{"issue":"3","key":"e_1_2_5_40_2","first-page":"128","article-title":"Somnolence as an adverse drug reaction of antiparkinsonian drugs: a meta\u2010analysis of published randomised placebo\u2010controlled trials","volume":"15","author":"Ferreira JJ","year":"2000","journal-title":"Mov Disord"},{"key":"e_1_2_5_41_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM197612162952504"},{"key":"e_1_2_5_42_2","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0031-6997(25)06826-7","article-title":"Bromocriptine in Parkinson's disease","volume":"37","author":"Lieberman AN","year":"1985","journal-title":"Pharmacol Rev"},{"issue":"10","key":"e_1_2_5_43_2","first-page":"50","article-title":"Dopaminergic agonists in the treatment of parkinsonism","volume":"40","author":"Goetz CG","year":"1990","journal-title":"Neurology"},{"key":"e_1_2_5_44_2","doi-asserted-by":"publisher","DOI":"10.1159\/000115567"},{"key":"e_1_2_5_45_2","first-page":"S2b98","article-title":"Role of dopaminergic agonists","volume":"156","author":"Rascol O","year":"2000","journal-title":"Rev Neurol (Paris)"},{"key":"e_1_2_5_46_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.56.suppl_5.S1"}],"container-title":["Movement Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fmds.10359","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/mds.10359","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:36:29Z","timestamp":1760956589000},"score":1,"resource":{"primary":{"URL":"https:\/\/movementdisorders.onlinelibrary.wiley.com\/doi\/10.1002\/mds.10359"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2003,1,24]]},"references-count":45,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2003,4]]}},"alternative-id":["10.1002\/mds.10359"],"URL":"https:\/\/doi.org\/10.1002\/mds.10359","archive":["Portico"],"relation":{},"ISSN":["0885-3185","1531-8257"],"issn-type":[{"value":"0885-3185","type":"print"},{"value":"1531-8257","type":"electronic"}],"subject":[],"published":{"date-parts":[[2003,1,24]]}}}